Literature DB >> 20096591

Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.

James J Fleming1, Pamela M England.   

Abstract

AMPA receptors are a family of ligand-gated ion channels that play central roles in rapid neural signaling and in regulation of synaptic strength. Additionally, these receptors are implicated in a number of major psychiatric and neurological diseases. A comprehensive understanding of the roles that AMPA receptors play in the mammalian nervous system has been hampered by the dearth of ligands available to select between individual AMPA receptors subtypes. Here we provide a perspective on opportunities for developing a complete pharmacology for AMPA receptors. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20096591     DOI: 10.1016/j.bmc.2009.12.072

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

Review 1.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

2.  Subunit-selective iGluR antagonists can potentiate heteromeric receptor responses by blocking desensitization.

Authors:  Stefan Pollok; Andreas Reiner
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-30       Impact factor: 11.205

3.  Distinct muscarinic acetylcholine receptor subtypes mediate pre- and postsynaptic effects in rat neocortex.

Authors:  Sylvain Gigout; Gareth A Jones; Stephan Wierschke; Ceri H Davies; Jeannette M Watson; Rudolf A Deisz
Journal:  BMC Neurosci       Date:  2012-04-27       Impact factor: 3.288

4.  AMPA receptors control fear extinction through an Arc-dependent mechanism.

Authors:  Simon Trent; Philip Barnes; Jeremy Hall; Kerrie L Thomas
Journal:  Learn Mem       Date:  2017-07-17       Impact factor: 2.460

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.